Search Results

Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study.

• Authors : Liu Y; Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.; Guo X

Subjects: Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/pathology ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/mortality

• Source: Cancer biology & medicine [Cancer Biol Med] 2024 Jul 26; Vol. 21 (9).Publisher: Chinese Anti-Cancer Association Country of Publication: China NLM ID: 101588850 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study.

• Authors : Jang DK; Kim SJ ...

Subjects: Ampulla of Vater*/Ampulla of Vater*/Ampulla of Vater*/pathology ; Palliative Care*/Palliative Care*/Palliative Care*/methods ; Adenocarcinoma*/Adenocarcinoma*/Adenocarcinoma*/drug therapy

• Source: Gut and liver [Gut Liver] 2024 Jul 15; Vol. 18 (4), pp. 729-736. Date of Electronic Publication: 2023 Dec 22.Publisher: Editorial Office of Gut and Liver Country of Publication: Korea (South) NLM ID: 101316452 Publication Model: Print-Electronic Cited Medium:

Record details

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma.

• Authors : Zhu Z; Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.; 4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

Subjects: Gemcitabine* ; Adenocarcinoma*; Humans

• Source: Cancer biology & medicine [Cancer Biol Med] 2023 Aug 29; Vol. 20 (10).Publisher: Chinese Anti-Cancer Association Country of Publication: China NLM ID: 101588850 Publication Model: Print Cited Medium: Internet ISSN:

Record details

A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.

• Authors : Chang C; Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.; Li X

Subjects: Gemcitabine* ; Adenocarcinoma*/Adenocarcinoma*/Adenocarcinoma*/pathology; Humans

• Source: The oncologist [Oncologist] 2023 Jul 05; Vol. 28 (7), pp. e575-e584.Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Agricola

Record details

Agricola

Record details

Thermosensitive Liposomes for Gemcitabine Delivery to Pancreatic Ductal Adenocarcinoma.

• Authors : Aparicio-Lopez, Cesar B.; Timmerman, Sarah; Lorino, Gabriella

Subjects: ADENOCARCINOMA; PHOSPHOLIPIDS; RESEARCH funding

• Source: Cancers; Sep2024, Vol. 16 Issue 17, p3048, 12p

Record details

Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.

• Authors : Buchholz, Marie; Majchrzak-Stiller, Britta; Peters, Ilka

Subjects: ADENOCARCINOMA; BIOLOGICAL models; IN vitro studies

• Source: Cancers; Jul2024, Vol. 16 Issue 14, p2612, 23p

Record details

Agricola

Record details

Severe and fatal interstitial lung disease induced by gemcitabine in advanced pancreatic adenocarcinoma: a case report.

• Authors : Haag, Edwin Kelly¹ (AUTHOR) ; Adjadé, Ganiou^1,2 (AUTHOR); Dawood, Héba² (AUTHOR)

Subjects: *GEMCITABINE; *INTERSTITIAL lung diseases; *ANTINEOPLASTIC agents

• Source: Oxford Medical Case Reports. Nov2023, Vol. 2023 Issue 11, p1-3. 3p.

Record details